Company news

Indivior Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes

February 11, 2025

Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month

October 29, 2024

Indivior Announces Q3 2024 Financial Results

October 23, 2024

Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion

October 9, 2024

Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review

October 6, 2024

Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder

September 3, 2024

Indivior Announces BARDA's First Order of OPVEE® to Combat Opioids and Aid in National Preparedness

August 25, 2024

Indivior Announces Q2 2024 Financial Results

July 24, 2024

Indivior Announces a New $100 Million Share Repurchase Program; New Program will be Executed Over an Accelerated Time Frame

July 24, 2024

Indivior Provides Business Update; Conference Call at 8: 00 AM U.S. EDT

July 8, 2024

Indivior Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (OPVEE 2.7mg) and IN Naloxone (4 mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression an...

June 17, 2024

Indivior Announces Dosing of First Subject with INDV-2000 in a Phase 2 Study Assessing the Safety and Efficacy of INDV-2000 in Individuals with Opioid Use Disorder

June 9, 2024

Indivior Announces Q1 2024 Financial Results

April 24, 2024

Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone

March 10, 2024

Indivior Announces Q4 / FY 2023 Financial Results

February 21, 2024

Indivior Announces Q3 2023 Financial Results

November 8, 2023

Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals

October 10, 2023

Indivior Publishes Real World Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in Canada

September 25, 2023

Indivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-District Litigation Claims

August 20, 2023

Indivior Announces Q2/H1 2023 Financial Results

July 26, 2023

Indivior Announces Four Abstracts Accepted for Presentation at the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence

June 13, 2023

← Newer news releases

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 43 decks. Every deck is listed under its year.